Trump administration halts Biden proposal to let Medicare, Medicaid cover anti-obesity drugs [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
of costly anti-obesity drugs to more than 7 million Americans on Medicare or Medicaid. The Centers for Medicare and Medicaid Services did not explain why it was not finalizing the proposal, which the Biden administration unveiled in November. However, the agency said in a statement that it may consider future policy options for anti-obesity medications “pending further review of both the potential benefits of these drugs including updated clinical indications, and relevant costs including fiscal impacts on stakeholders such as state Medicaid agencies.” Ad Feedback New US Health and Human Services Secretary Robert F. Kennedy Jr. has made statements strongly disapproving of the medications in the past, although his new CMS administrator, Dr. Mehmet Oz, frequently touted anti-obesity drugs on his television show and on social media. But expanding coverage would have been expensive, and the Trump administration and Elon Musk's Department of Government Efficiency have said that sla
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]Yahoo! Finance
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]Yahoo! Finance
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website